Please login to the form below

Not currently logged in

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year


Johnson & Johnson has an FDA green light to start a new trial of the CAR-T therapy for multiple myeloma it licensed from China’s Legend Biotech for a whopping $350m upfront last December.

Legend’s anti-BCMA CAR-T - called LCAR-B38M and now rebadged as JNJ-68284528 by J&J’s Janssen division - hit the headlines at last year’s American Society of Clinical Oncology (ASCO) meeting after Legend presented stellar data from an early-stage trial that showed a 100% objective response rate in treatment-resistant, relapsed myeloma patients.

The new phase I/II trial, due to get underway in the second half of the year, will also enrol patients with relapsed or refractory multiple myeloma and will start with a phase 1b trial to determine a suitable dose to take forward to the phase II portion, which will gauge efficacy using overall response rate as a primary endpoint.

J&J is going up against some well-positioned competitors in the anti-BCMA CAR-T category, notably Celgene and Bluebird Bio with bb2121, Celgene and Juno with and Kite Pharma/Gilead Sciences’ KITE-585, both of which are on the agenda of this year’s ASCO which gets underway on Friday.

There are other candidates in the pipeline too, including TeneoBio’s TNB-383B, a therapy developed by China’s Pregene Biotech, as well as at least three others in investigator-sponsored trials in China and the US.

In the US alone, there are more than 30,000 new cases of myeloma every year, causing around 12,000 deaths a year and - despite an increasing number of treatment options - the disease remains incurable and CAR-T is viewed as a potentially important new treatment option.

The start of the trial is another signpost on J&J’s road to developing a position in cancer immunotherapy as it tries to catch the leaders in the category such as Bristol-Myers Squibb, Merck & Co and Roche.

Earlier this month it bought oncolytic virus player Benevir Biopharm for $140m upfront and up to $900m in milestones, and also has a collaboration with Aduro for cancer vaccine ADU-214 as well as some in-house projects such as PD-1 checkpoint inhibitor JNJ-63723283, but it is still a minnow among the big fish in immuno-oncology.

Meanwhile, hopes that its anti-CD38 Darzalex (daratumumab) could find a role alongside checkpoint inhibitors in blood cancers and solid tumours took a knock earlier this week after safety issues led to two the termination of two trials of the drug in combination with Roche’s Tecentriq (atezolizumab) and JNJ-63723283.

Article by
Phil Taylor

31st May 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...